| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KIR2DS2 |
| Uniprot No | P43631 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-304aa |
| 氨基酸序列 | MSLMVVSMACVGFFLLQGAWPHEGVHRKPSLLAHPGPLVKSEETVILQCWSDVRFEHFLLHREGKYKDTLHLIGEHHDGVSKANFSIGPMMQDLAGTYRCYGSVTHSPYQLSAPSDPLDIVITGLYEKPSLSAQPGPTVLAGESVTLSCSSRSSYDMYHLSREGEAHERRFSAGPKVNGTFQADFPLGPATHGGTYRCFGSFRDSPYEWSNSSDPLLVSVTGNPSNSWPSPTEPSSKTGNPRHLHVLIGTSVVKIPFTILLFFLLHRWCSNKKNAAVMDQEPAGNRTVNSEDSDEQDHQEVSYA |
| 预测分子量 | 33,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KIR2DS2重组蛋白的示例性参考文献(注：部分内容为示例性概括，实际文献需通过学术数据库查询)：
---
1. **文献名称**: *"Functional Characterization of Recombinant KIR2DS2 Reveals HLA-C-Specific Activation in NK Cells"*
**作者**: Smith A, et al.
**摘要**: 本研究成功表达并纯化KIR2DS2重组蛋白，证实其与HLA-C1抗原的特异性结合。通过体外实验证明，KIR2DS2-HLA-C1相互作用可增强NK细胞的细胞毒性及细胞因子分泌，提示其在抗病毒免疫中的潜在作用。
2. **文献名称**: *"Structural Insights into KIR2DS2 Signaling Mechanism via Recombinant Protein Crystallography"*
**作者**: Chen L, et al.
**摘要**: 通过X射线晶体学解析KIR2DS2胞外结构域的三维结构，发现其D0和D2结构域的独特构象可能影响配体结合。重组蛋白实验表明，特定氨基酸残基突变会显著降低其与HLA的亲和力，为靶向治疗提供结构基础。
3. **文献名称**: *"Association of KIR2DS2 Recombinant Protein with Autoimmune Disease Risk in HLA-Dependent Pathways"*
**作者**: García-Ruiz C, et al.
**摘要**: 利用KIR2DS2重组蛋白分析其与HLA的相互作用，发现携带HLA-C*06:02等位基因的个体中，KIR2DS2过度激活NK细胞可能导致银屑病等自身免疫疾病的易感性增加，提示基因-受体互作在病理中的关键作用。
---
**建议**：如需真实文献，可通过PubMed或Google Scholar检索关键词“KIR2DS2 recombinant protein”或结合具体研究领域(如结构、疾病关联)进一步筛选。
KIR2DS2 is a member of the killer-cell immunoglobulin-like receptor (KIR) family, which regulates natural killer (NK) cell activity and adaptive immune responses. These receptors are primarily expressed on NK cells and a subset of T lymphocytes, interacting with human leukocyte antigen (HLA) class I molecules to balance immune activation and inhibition. KIR2DS2. classified as an activating receptor due to its short cytoplasmic tail and association with adaptor proteins like DAP12. contains two extracellular immunoglobulin-like domains (D0 and D2) and binds selectively to HLA-C allotypes displaying a C1 epitope (e.g., HLA-C*01. *03. *07). This interaction triggers NK cell cytotoxicity and cytokine production, influencing antiviral defense, tumor surveillance, and autoimmune pathologies.
Recombinant KIR2DS2 protein is engineered using expression systems (e.g., mammalian cells, CHO lines) to produce soluble, functional forms of the receptor. Techniques often involve fusing the extracellular domain with tags (Fc, His) for purification and detection. This protein serves as a critical tool for studying ligand specificity, signaling mechanisms, and receptor-ligand structural dynamics. Research has linked KIR2DS2 polymorphisms to disease susceptibility, including hepatitis C clearance, rheumatoid arthritis, and pregnancy complications, highlighting its dual role in protection and immunopathology. Clinically, recombinant KIR2DS2 aids in developing immunotherapies, such as blocking antibodies for autoimmune disorders or engineered NK cell therapies for cancer. Challenges remain in understanding its context-dependent functions, particularly how genetic diversity and HLA-KIR combinations modulate immune outcomes.
×
